Cargando…

Elimination of Mutant mtDNA by an Optimized mpTALEN Restores Differentiation Capacities of Heteroplasmic MELAS-iPSCs

Various mitochondrial diseases, including mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), are associated with heteroplasmic mutations in mitochondrial DNA (mtDNA). Herein, we refined a previously generated G13513A mtDNA-targeted platinum transcription activator-like...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yahata, Naoki, Boda, Hiroko, Hata, Ryuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7744650/ https://www.ncbi.nlm.nih.gov/pubmed/33376755 http://dx.doi.org/10.1016/j.omtm.2020.10.017

Ejemplares similares

TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation
por: Yahata, Naoki, et al.
Publicado: (2017)

Author Correction: TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513 G>A mutation
por: Yahata, Naoki, et al.
Publicado: (2018)

Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs
por: Yang, Yi, et al.
Publicado: (2018)

Modulation of mtDNA copy number ameliorates the pathological consequences of a heteroplasmic mtDNA mutation in the mouse
por: Filograna, R., et al.
Publicado: (2019)

Selection of iPSCs without mtDNA deletion for autologous cell therapy in a patient with Pearson syndrome
por: Lee, Yeonmi, et al.
Publicado: (2023)

A Naturally Heteroplasmic Clam Provides Clues about the Effects of Genetic Bottleneck on Paternal mtDNA
por: Iannello, Mariangela, et al.
Publicado: (2021)

Oxygen tension modulates the mitochondrial genetic bottleneck and influences the segregation of a heteroplasmic mtDNA variant in vitro
por: Pezet, Mikael G., et al.
Publicado: (2021)

Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance
por: Arthur, Charles R, et al.
Publicado: (2009)

MELAS and Kearns–Sayre overlap syndrome due to the mtDNA m. A3243G mutation and large-scale mtDNA deletions
por: Yu, Nian, et al.
Publicado: (2016)

Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS‐associated mtDNA mutations
por: Gramegna, Laura L., et al.
Publicado: (2021)

Mutant C. elegans mitofusin leads to selective removal of mtDNA heteroplasmic deletions across generations to maintain fitness
por: Meshnik, Lana, et al.
Publicado: (2022)

Editor’s Note: A Naturally Heteroplasmic Clam Provides Clues about the Effects of Genetic Bottleneck on Paternal mtDNA
Publicado: (2021)

HLA DR Genome Editing with TALENs in Human iPSCs Produced Immune-Tolerant Dendritic Cells
por: Kwon, Yoo-Wook, et al.
Publicado: (2021)

Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation
por: Emperador, Sonia, et al.
Publicado: (2019)

Reducing the Number of Mismatches between Hairs and Buccal References When Analysing mtDNA Heteroplasmic Variation by Massively Parallel Sequencing
por: van der Gaag, Kristiaan J., et al.
Publicado: (2020)

Deficiency in MT5-MMP Supports Branching of Human iPSCs-Derived Neurons and Reduces Expression of GLAST/S100 in iPSCs-Derived Astrocytes
por: Arnst, Nikita, et al.
Publicado: (2021)

Non-Random mtDNA Segregation Patterns Indicate a Metastable Heteroplasmic Segregation Unit in m.3243A>G Cybrid Cells
por: Raap, Anton K., et al.
Publicado: (2012)

Lucky iPSCs
por: Zviran, Asaf, et al.
Publicado: (2014)

iPSCs are safe!
por: Yan, Hualong, et al.
Publicado: (2017)

Late-onset MELAS syndrome with mtDNA 14453G→A mutation masquerading as an acute encephalitis: a case report
por: Yokota, Yuki, et al.
Publicado: (2020)

Both TALENs and CRISPR/Cas9 directly target the HBB IVS2–654 (C > T) mutation in β-thalassemia-derived iPSCs
por: Xu, Peng, et al.
Publicado: (2015)

Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs
por: Gammage, Payam A., et al.
Publicado: (2016)

Ancient mtDNA Genetic Variants Modulate mtDNA Transcription and Replication
por: Suissa, Sarit, et al.
Publicado: (2009)

In vivo methylation of mtDNA reveals the dynamics of protein–mtDNA interactions
por: Rebelo, Adriana P., et al.
Publicado: (2009)

Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo
por: Zekonyte, Ugne, et al.
Publicado: (2021)

Targeted Integration of Inducible Caspase-9 in Human iPSCs Allows Efficient in vitro Clearance of iPSCs and iPSC-Macrophages
por: Lipus, Alexandra, et al.
Publicado: (2020)

Mitochondria fingerprint longevity in iPSCs
por: Masotti, Andrea, et al.
Publicado: (2015)

Applications of iPSCs in Cancer Research
por: Kim, Jean J
Publicado: (2015)

Reducing genomic instability in iPSCs
por: Ruiz, Sergio, et al.
Publicado: (2015)

The Challenge of Bringing iPSCs to the Patient
por: Ortuño-Costela, María del Carmen, et al.
Publicado: (2019)

iPSCs in Modeling and Therapy of Osteoarthritis
por: Csobonyeiova, Maria, et al.
Publicado: (2021)

mt tRFs, New Players in MELAS Disease
por: Meseguer, Salvador, et al.
Publicado: (2022)

New Variant of MELAS Syndrome With Executive Dysfunction, Heteroplasmic Point Mutation in the MT-ND4 Gene (m.12015T>C; p.Leu419Pro) and Comorbid Polyglandular Autoimmune Syndrome Type 2
por: Endres, Dominique, et al.
Publicado: (2019)

TALENs Facilitate Single-step Seamless SDF Correction of F508del CFTR in Airway Epithelial Submucosal Gland Cell-derived CF-iPSCs
por: Suzuki, Shingo, et al.
Publicado: (2016)

Where mtDNA is made
por: LeBrasseur, Nicole
Publicado: (2003)

Melanesian mtDNA Complexity
por: Friedlaender, Jonathan S., et al.
Publicado: (2007)

Commentary: New Variant of MELAS Syndrome With Executive Dysfunction, Heteroplasmic Point Mutation in the MT-ND4 Gene (m.12015T>C; p.Leu419Pro) and Comorbid Polyglandular Autoimmune Syndrome Type 2
por: Finsterer, Josef
Publicado: (2019)

iPSCs: From Bench to Clinical Bed
por: Li, Yujing, et al.
Publicado: (2016)

Differentiation of human iPSCs into functional podocytes
por: Rauch, Caroline, et al.
Publicado: (2018)

Healthy, mtDNA-mutation free mesoangioblasts from mtDNA patients qualify for autologous therapy
por: van Tienen, Florence, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_79s5gqsp5k64k45om56shu54rc